Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 4/2023

01-08-2023 | Portal Vein Thrombosis

Portal Vein Thrombosis in Adults without Cirrhosis

Authors: Franklyn Wallace, Douglas A Simonetto

Published in: Current Hepatology Reports | Issue 4/2023

Login to get access

Abstract

Purpose of Review

The management of non-cirrhotic, non-tumoral portal vein thrombosis (PVT) has historically been challenging due to a paucity of data. The purpose of this review is to summarize the recommendations from major society guidelines and to highlight emerging evidence from recent years.

Recent Findings

While direct oral anticoagulants are increasingly used for the treatment of non-cirrhotic PVT, prospective comparison with warfarin or low molecular weight heparin remains uninvestigated in this population. There is growing evidence that optimal treatment requires a tailored approach based on the underlying etiology of PVT, with options ranging from a relatively short course of anticoagulation to an aggressive combined medical/procedural approach.

Summary

Anticoagulation remains the mainstay of treatment for non-cirrhotic PVT. Current therapies are effective at reducing the risk of both immediate complications and long-term sequelae. Future studies should focus on refining the preferred approach to treatment based on etiology of PVT.
Literature
1.
Francoz C, Valla D, Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J Hepatol. 2012;57(1):203–12.CrossRefPubMed
2.
Connolly GC, Chen R, Hyrien O, Mantry P, Bozorgzadeh A, Abt P, et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res. 2008;122(3):299–306.CrossRefPubMed
3.
Ageno W, Dentali F, Pomero F, Fenoglio L, Squizzato A, Pagani G, et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome. Thromb Haemost. 2017;117(04):794–800.CrossRefPubMed
4.
Rajani R, Björnsson E, Bergquist A, Danielsson Å, Gustavsson A, Grip O, et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study: the epidemiology and clinical features of portal vein thrombosis. Aliment Pharmacol Ther. 2010;32(9):1154–62.CrossRefPubMed
5.
Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology. 2019;156(6):1582–1599.e1.CrossRefPubMed
6.
Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010;51(1):210–8.CrossRefPubMed
7.
Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG clinical guideline: disorders of the hepatic and mesenteric circulation. Am J Gastroenterol. 2020;115(1):18–40.CrossRefPubMed
8.
Lee HK, Park SJ, Yi BH, Yeon EK, Kim JH, Hong HS. Portal vein thrombosis: CT features. Abdom Imaging. 2008;33(1):72–9.CrossRefPubMed
9.
Elkrief L, Houssel-Debry P, Ackermann O, Franchi-Abella S, Branchereau S, Valla D, et al. Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction. Clin Res Hepatol Gastroenterol. 2020;44(4):491–6.CrossRefPubMed
10.
Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the american association for the study of liver diseases. Hepatology. 2021;73(1):366–413.CrossRefPubMed
11.
• Minoda AM, RBF C, Teixeira SR, Muglia VF, Elias Junior J, AFD M-L. The ABCD of portal vein thrombosis: a systematic approach. Radiol Bras. 2020;53(6):424–9. This is a thorough review of the imaging features associated with acute and chronic PVT which can be exceptionally valuable to a clinician evaluiating a patient at a single point in time. The information in this article forms the basis for Table 2 within the article.CrossRefPubMedPubMedCentral
12.
Kalra N, Shankar S, Khandelwal N. Imaging of portal cavernoma cholangiopathy. J Clin Exp Hepatol. 2014;4:S44–52.CrossRefPubMed
13.
Stefano VD, Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost. 2016;115(02):240–9.CrossRefPubMed
14.
•• Liu A, Naymagon L, Tremblay D. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment considerations and unmet needs. Cancers. 2022;15(1):11. This article provides a practical summary of the unique multidisciplinary management required for treating patients with PVT occurring in the context of a myeloproliferative neoplasm.CrossRefPubMedPubMedCentral
15.
Brunaud L, Antunes L, Collinet-Adler S, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: case for nonoperative management. J Vasc Surg. 2001;34(4):673–9.CrossRefPubMed
16.
Acosta S, Salim S. Management of acute mesenteric venous thrombosis: a systematic review of contemporary studies. Scand J Surg. 2021;110(2):123–9.CrossRefPubMed
17.
Fusaro L, Di Bella S, Martingano P, Crocè LS, Giuffrè M. Pylephlebitis: a systematic review on etiology, diagnosis, and treatment of infective portal vein thrombosis. Diagnostics. 2023;13(3):429.CrossRefPubMedPubMedCentral
18.
Naymagon L, Tremblay D, Schiano T, Mascarenhas J. The role of anticoagulation in pylephlebitis: a retrospective examination of characteristics and outcomes. J Thromb Thrombolysis. 2020;49(2):325–31.CrossRefPubMed
19.
Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Troy K, Schiano T, et al. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv. 2020;4(4):655–66.CrossRefPubMedPubMedCentral
20.
Turnes J, Garcia-Pagan JC, González M, Aracil C, Calleja JL, Ripoll C, et al. Portal hypertension–related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol. 2008;6(12):1412–7.CrossRefPubMed
21.
Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Naymagon S, Mascarenhas J, et al. The natural history, treatments, and outcomes of portal vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(2):215–23.CrossRefPubMed
22.
Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Schiano T, Mascarenhas J. Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation. J Thromb Thrombolysis. 2020;50(3):652–60.CrossRefPubMed
23.
Kodali S, Singal AK. Portal and mesenteric venous thrombosis. Clin Liver Dis. 2020;16(4):142–5.CrossRef
24.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74.CrossRefPubMed
25.
Orr DW, Harrison PM, Devlin J, Karani JB, Kane PA, Heaton ND, et al. Chronic mesenteric venous thrombosis: evaluation and determinants of survival during long-term follow-up. Clin Gastroenterol Hepatol. 2007;5(1):80–6.CrossRefPubMed
26.
Spaander MCW, Hoekstra J, Hansen BE, Van Buuren HR, Leebeek FWG, Janssen HLA. Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. J Thromb Haemost. 2013;11(3):452–9.CrossRefPubMed
27.
Noronha Ferreira C, Seijo S, Plessier A, Silva-Junior G, Turon F, Rautou P, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology. 2016;63(5):1640–50.CrossRefPubMed
28.
Duseja A. Portal cavernoma cholangiopathy—clinical characteristics. J Clin Exp Hepatol. 2014;4:S34–6.PubMed
29.
Dhiman RK, Saraswat VA, Valla DC, Chawla Y, Behera A, Varma V, et al. Portal cavernoma cholangiopathy: consensus statement of a working party of the indian national association for study of the liver. J Clin Exp Hepatol. 2014;4:S2–14.CrossRefPubMedPubMedCentral
30.
Saraswat VA, Rai P, Kumar T, Mohindra S, Dhiman RK. Endoscopic management of portal cavernoma cholangiopathy: practice, principles and strategy. J Clin Exp Hepatol. 2014;4:S67–76.CrossRefPubMed
31.
Zhang AD, Bergen M. Novel technique in treating portal cavernous transformation with portal Biliopathy. J Natl Med Assoc. 2022;114(5):495–7.PubMed
32.
Varma V, Behera A, Kaman L, Chattopadhyay S, Nundy S. Surgical management of portal cavernoma cholangiopathy. J Clin Exp Hepatol. 2014;4:S77–84.CrossRefPubMed
33.
Huang L, Yu QS, Zhang Q, Liu JD, Wang Z. Transjugular intrahepatic portosystemic shunt versus surgical shunting in the management of portal hypertension. Chin Med J. 2015;128(6):826–34.CrossRefPubMedPubMedCentral
34.
• Ageno W, Beyer Westendorf J, Contino L, Bucherini E, Sartori MT, Senzolo M, et al. Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Adv. 2022;6(12):3569–78. Provides the first direct evdience supporting the use of DOACs in the treatment of noncirrhotic PVT.CrossRefPubMedPubMedCentral
35.
Plessier A, Goria O, Cervoni JP, Ollivier I, Bureau C, Poujol-Robert A, et al. Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis. NEJM Evid. 2022;1(12).
36.
Cheng Q, Tree K. Systematic review of thrombolysis therapy in the management of non-cirrhosis-related portal vein thrombosis. J Gastrointest Surg. 2021;25(6):1579–90.CrossRefPubMed
37.
Rössle M, Bettinger D, Trebicka J, Klinger C, Praktiknjo M, Sturm L, et al. A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatment. Aliment Pharmacol Ther. 2020;52(2):329–39.CrossRefPubMed
38.
Marot A, Barbosa JV, Duran R, Deltenre P, Denys A. Percutaneous portal vein recanalization using self-expandable nitinol stents in patients with non-cirrhotic non-tumoral portal vein occlusion. Diagn Interv Imaging. 2019;100(3):147–56.CrossRefPubMed
39.
Valentin N, Korrapati P, Constantino J, Young A, Weisberg I. The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(10):1187–93.CrossRefPubMed
40.
Kallini JR, Gabr A, Kulik L, Ganger D, Lewandowski R, Thornburg B, et al. Noncirrhotic complete obliterative portal vein thrombosis: novel management using trans-splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization. Hepatology. 2016;63(4):1387–90.CrossRefPubMed
Metadata
Title
Portal Vein Thrombosis in Adults without Cirrhosis
Authors
Franklyn Wallace
Douglas A Simonetto
Publication date
01-08-2023

Other articles of this Issue 4/2023

Current Hepatology Reports 4/2023 Go to the issue

ReviewPaper

Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy

ReviewPaper

What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications

ReviewPaper

Obliterative Portal Venopathy

ReviewPaper

Diagnosis and Management of Noncirrhotic Portal Hypertension

ReviewPaper

Risk of Liver Cancer in MASLD: Role of Genetic Risk Scores

ReviewPaper

Interventional Radiology and Surgical Treatment Options for Non-Cirrhotic Portal Hypertension
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits